![]() ![]() Regardless of their approach, most cities can't afford to lose the tourism dollars that flow from short-term rentals. Other places have cracked down and capped the number of permits, pacifying concerned citizens and preserving the profits of existing Airbnb owners. Some cities have allowed vacation-rental listings to multiply virtually unchecked, setting the stage for an oversupply that has come back to bite investors. Rather than a collapse of the industry, the increasingly bifurcated state of the market - a bust for some, a boom for others - is a clear sign that we have hit a turning point in the long-running battle over short-term rentals. The number of nights booked at US short-term rentals reached a record high in 2022, as did total revenue, according to AirDNA, which tracks properties listed on the vacation-rental sites Airbnb and Vrbo. It often indicates a user profile.īut the hand-wringing over the idea of a downturn ignores a conflicting, but undeniable, reality: The short-term-rental business is bigger than ever, and some operators are thriving like never before. To read this article on click here.Account icon An icon in the shape of a person's head and shoulders. (SRPT) : Free Stock Analysis ReportĮxact Sciences Corporation (EXAS) : Free Stock Analysis Report Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Exact Sciences. Over the last 30 days, the Zacks Consensus Estimate has changed +1.7%. EPS of -$0.72 for the same period compares with -$1.28 a year ago.Įxact Sciences is expected to post a loss of $0.79 per share for the current quarter, representing a year-over-year change of +24%. The company reported its results for the quarter ended December 2022 more than a month ago.Įxact Sciences reported revenues of $553 million in the last reported quarter, representing a year-over-year change of +16.7%. Over the past month, Exact Sciences (EXAS), a stock from the same industry, has gained 7.5%. Sarepta Therapeutics is part of the Zacks Medical - Biomedical and Genetics industry. We expect an in-line return from the stock in the next few months. Notably, Sarepta Therapeutics has a Zacks Rank #3 (Hold). If you aren't focused on one strategy, this score is the one you should be interested in.Įstimates have been broadly trending upward for the stock, and the magnitude of these revisions indicates a downward shift. Overall, the stock has an aggregate VGM Score of C. Charting a somewhat similar path, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for this investment strategy. The consensus estimate has shifted -10% due to these changes.Īt this time, Sarepta Therapeutics has a great Growth Score of A, though it is lagging a lot on the Momentum Score front with an F. ![]() It turns out, estimates review have trended upward during the past month. How Have Estimates Been Moving Since Then? The company expects to generate more than $925 million in product revenues from its three approved PMO therapies. This surge is attributable to the increase in manufacturing expenses for ramping up production for SRP-9001.Īdjusted selling, general & administrative (SG&A) expenses were $86.6 million, up 44.1% year over year. In the year-ago period, management had recorded $22.7 million as collaboration revenues, which were also received from Roche.Īdjusted research and development (R&D) expenses totaled $186.8 million in the fourth quarter, up 6.4% year over year. The company recorded $22.5 million in collaboration revenues, primarily from its licensing agreement with Roche. The upside was driven by an increase in demand for its DMD products. ![]() The company derived product revenues of $235.9 million, up 32.0% year over year. The year-over-year increase in revenues was driven by the sales of Sarepta’s three currently approved RNA-based PMO therapies for DMD,Exondys 51, Vyondys 53 and Amondys 45. Revenues beat the Zacks Consensus Estimate of $249.4 million. Sarepta recorded total revenues of $258.4 million, up 28.3% year over year. The adjusted figure excludes one-time items, depreciation and amortization expenses, interest expenses, income tax benefit, stock-based compensation expenses and other items. The company reported an adjusted loss of 53 cents per share compared with an adjusted loss of 77 cents in the year-ago quarter. The loss was also narrower than the year-ago quarter’s loss of $1.42 per share. Sarepta reported a loss of $1.24 per share in the fourth quarter of 2022, narrower than the Zacks Consensus Estimate of a loss of $1.28 per share. ![]()
0 Comments
Leave a Reply. |